Page 18 - Observational Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail The use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, does not lead to higher rates of death or severe disease in patients who are hospitalised with COVID-19, according to a new observational study of more than 72,000 people in the UK published in The Lancet Rheumatology journal. NSAIDs are common treatments for acute pain and rheumatological diseases such as rheumatoid arthritis and osteoarthrosis. Early in the pandemic, there was debate on whether the use of such drugs increased the severity of COVID-19, which led to urgent calls for investigations betwee...

Drinking This Increases Your Risk of Skin Cancer, New Study Says © Provided by Eat This, Not That! drinking juice outside If you enjoyed a Cinco de Mayo margarita last night, then you might want to add a little extra sunscreen this morning. That's according to a new study, which found a link between drinking a certain type of juice, and increased skin cancer risk. May happens to be Skin Cancer Awareness Month, and a group of researchers at various universities throughout New England have just published a new study in Cancers, a peer-reviewed Swiss medical journal. They were aware of past...

Share this article SELBYVILLE, Del., April 19, 2021 /PRNewswire/ -- According to latest report "Clinical Trial Market by Phases (Phase I, Phase II, Phase III, Phase IV), Study Design (Interventional Study, Observational Study, Expanded Access Study), Therapeutic Area (Autoimmune Disease, Oncology, Cardiology, Infectious Disease, Dermatology, Ophthalmology), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2027", by Global Market Insights Inc., the market valuation of clinical trials will cross $59.6 billion by 2027. Major clinical trial market players include Laboratory ...

Nova Mentis Launches Autism Microbiome Study in the United States News provided by Share this article Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF)  ("NOVA" or the "Company"), a leader in the development of psilocybin and other entheogens, is pleased to announce the launch of its US-based Observational Study NM-101: " Microbiotic Diversity in Autism Spectrum Disorder (ASD): Improving Diagnostics by Differentiating Subtypes." "NOVA's mission is to discover more precise ways to diagnose and treat autism spectrum disorder (ASD), an unmet medical need," stated Julia V. ...

Price Change: $0.012 Unchanged If you would like more information on future Peak deals, please don’t hesitate to get in touch. Follow Peak Asset The trustee for Peak Asset Management Unit Trust (“Peak”) is a corporate authorised representative (#1249050) of Equity Underwriters Pty Ltd (AFSL #244040). Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does...